Navigation Links
Zonisamide in Medical News

Ranbaxy Ties Up With US Co For Mktg Zonisamide Capsules

Pharma major Ranbaxy Laboratories Ltd has entered into a strategic partnership with US-based Invagen Pharmaceuticals Inc for marketing Zonisamide Capsules // , which are used for the treatment of epilepsy, in the US market. Under the agreement products would be developed and submitted for appr...

FDA Adds Suicide Warning to Epilepsy Drugs

...); methosuximide (Celontin); oxcarbazepine (Trileptal); pregabalin (Lyrica); primidone (Mysoline); tiagabine (Gabitril); trimethadione (Tridione), and zonisamide (Zonegran). Some of these drugs are also available as generics. According to the FDA, antiepileptic drugs are used to treat epilepsy, bipolar disor...

FDA Advisers Don't Back 'Black Box' Warning for Epilepsy Drugs

...d as Lyrica), Tiagabine (marketed as Gabitril), Topiramate (marketed as Topamax), Valproate (marketed as Depakote, Depakote ER, Depakene, Depacon) and zonisamide (marketed as Zonegran). Some of these drugs are also available as generics. According to the FDA, antiepileptic drugs are used to treat epilepsy, b...

FDA Advisers Don't Back Epilepsy Drug Warnings

...d as Lyrica), Tiagabine (marketed as Gabitril), Topiramate (marketed as Topamax), Valproate (marketed as Depakote, Depakote ER, Depakene, Depacon) and zonisamide (marketed as Zonegran). Some of these drugs are also available as generics. According to the FDA, antiepileptic drugs are used to treat epilepsy, b...

Epilepsy Drugs Can Cause Suicidal Tendencies, FDA Panel Finds

...d as Lyrica), Tiagabine (marketed as Gabitril), Topiramate (marketed as Topamax), Valproate (marketed as Depakote, Depakote ER, Depakene, Depacon) and zonisamide (marketed as Zonegran). Some of these drugs are also available as generics. According to the FDA, antiepileptic drugs are used to treat epilepsy, b...

FDA Warns Epilepsy Drugs May Raise Suicide Risk

...d as Lyrica), Tiagabine (marketed as Gabitril), Topiramate (marketed as Topamax), Valproate (marketed as Depakote, Depakote ER, Depakene, Depacon) and zonisamide (marketed as Zonegran). Some of these drugs are also available as generics. According to the FDA, antiepileptic drugs are used to treat epilepsy, b...

Pipeline for New Obesity Therapies is Focus of New Report

...s), LH-21 (Instituto de Quimica Medica), Qnexa (phentermine / topiramate; Vivus), Contrave (bupropion / naltrexone; Orexigen), Empatic (bupropion SR + zonisamide SR; Orexigen), Meridia (sibutramine; Abbott), lorcaserin (APD356; Arena), Byetta (exenatide; Amylin/Lilly), exenatide LAR (Lilly/Amylin/Alkermes), exe...
Zonisamide in Medical Technology

Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)

...ic(TM) Empatic is a fixed dose combination of bupropion SR with our proprietary sustained release formulation of zonisamide. Research indicates that zonisamide inhibits AgRP, a system associated with increasing appetite while bupropion increases metabolism. Based on the strength of these results and the uniqu...

Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule

...o exceed $100 billion annually. Empatic combines zonisamide and bupropion, two existing drugs that have been i... proprietary sustained release (SR) formulation of zonisamide that has demonstrated a better tolerability profil.... The efficacy of Empatic will be compared against zonisamide monotherapy, bupropion monotherapy and placebo. Tr...

OREXIGEN Therapeutics Announces Sustained-Release Formulation of Zonisamide Shows Improved Tolerability When Compared to Immediate Release Formulation

... Orexigen(TM) is evaluating zonisamide SR as a novel component in EMPATIC(TM) Phase IIb o...of zonisamide. In the study, the SR formulation of zonisamide achieved a significant reduction in the incidence ... to an immediate release (IR), legacy formulation. zonisamide SR is a key component in the Company's obesity pro...
Zonisamide in Biological Technology

Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union

...Bial towards bringing to patients such a promising new treatment for epilepsy. Zebinix(R) joins our existing family of anti-epileptics, which includes zonisamide and rufinamide and a new molecule currently entering phase three clinical development studies. When launched, Zebinix(R) will help us to fulfil our Co...

Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results

... proprietary sustained release (SR) formulation of zonisamide plus olanzapine. The Phase 2a clinical trial, OZ-1.... 7,425,571 providing broad coverage of the use of zonisamide either alone or in combination with other drugs fo...ued U.S. Patent No. 7,429,580 which broadly covers zonisamide in combination with various marketed atypical anti...

Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain

... - Two Milestones Reached in zonisamide Patent Portfolio - SAN DIEGO, Oct. 2 /PRNewswire...03, a proprietary sustained release formulation of zonisamide plus olanzapine. The Phase 2a clinical trial, OZ-1.... 7,425,571 providing broad coverage of the use of zonisamide either alone or in combination with other drugs fo...

Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting

...m Weight Loss from a Dose Optimization Study with zonisamide SR and Bupropion SR" Time: 11:00-11:15 a.m. MT ... Improvements from a Dose Optimization Study with zonisamide SR and Bupropion SR" Time: 12:45-2:45 p.m. MT P...ng of Response from a Dose Optimization Study with zonisamide SR and Bupropion SR" Time: 12:45-2:45 p.m. MT ...

OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003

...broad coverage for a pharmaceutical composition of zonisamide in combination with a series of marketed atypical ...ed blood glucose associated with olanzapine alone. zonisamide appears to reverse the olanzapine effects on appet...l trials. If issued, this patent will also cover zonisamide in combination with other atypical antipsychotics,...
Other Tags
(Date:8/1/2015)... ... August 01, 2015 , ... Tina Wilcoxson, owner of Freeport ... was given that honor by the National Retail Federation, the largest retail trade association ... one of three Maine business owners to be named as such. According to the ...
(Date:8/1/2015)... ... August 01, 2015 , ... ... (“GPP”) portfolio company has acquired Premier Physical Therapy & Wellness (“Premier”) — with ... of state-of-the-art clinics. , “Our acquisition of Premier Physical Therapy & Wellness solidifies ...
(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... Lume Wellness ... that is free to download on the Apple AppStore. , The app is ... even mood, thus acting as a tool to view personal health and use this ...
(Date:8/1/2015)... ... 01, 2015 , ... “ reTXT ” was featured on NewsWatch as part ... on the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch ... clarify, edit and delete any message including ones already sent. , While text messaging ...
(Date:7/31/2015)... Santa Rosa, CA (PRWEB) , ... July 31, ... ... been posted by High Times magazine. What are the STASH awards? The ... celebrate advances made by the cannabis-cultivation community as well as tried-and-true products that ...
Breaking Medicine News(10 mins):Health News:Local Retail Advocate Wins National Recognition 2Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2
(Date:7/7/2015)... Calif. , July 7, 2015  Based ... market, Frost & Sullivan recognizes Credence ID, LLC ... Entrepreneurial Company of the Year Award. Credence ... to aid in its mission of offering enrollment ... populations globally. As Credence ID was formed by ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) ... Biometrics Market by Application, Technology, Function & Geography - ... The next generation biometrics market is expected ... of 17.9% between 2015 and 2020 Travel ... Safran SA ( France ), ...
(Date:6/30/2015)... , June 30, 2015 Genisphere ... company as CEO to help further develop Genisphere,s therapeutics ... of partnering experience, having spent much of the last ... Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. Tom ... on Technology and Biotech Corporate Finance. He graduated from ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
Other Contents